Evidence map›Paper›PMID 36242622›Full record

Trial reportArchives of dermatological research2023

A comparative study on a biodegradable hyaluronic acid microneedle patch with a needleless patch for dry skin in atopic dermatitis: a single-blinded, split-body, randomized controlled trial.

Ji-Hoon Song, Eun Jin An, Chang Yub Sung, Do Hyeon Jeong, Gihyun Lee, Soo-Yeon Park

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Archives of dermatological research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Hyaluronic Acid ProfhiloMedicina (Kaunas, Lithuania) · 2026
    Article
  3. Microneedles in Allergy Immunotherapy: the Present and Future.Current allergy and asthma reports · 2025
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ji-Hoon SongDepartment of Ophthalmology, Otolaryngology and Dermatology, College of Korean Medicine, Dongshin University, 120-9, Dongsindae-gil, Naju-si, Jeollanam-do, 58245, Republic of Korea.
Eun Jin AnRaphas Co., Ltd., 62, Magokjungang 8-ro 1-gil, Gangseo-gu, Seoul, 07793, Republic of Korea.
Chang Yub SungRaphas Co., Ltd., 62, Magokjungang 8-ro 1-gil, Gangseo-gu, Seoul, 07793, Republic of Korea.
Do Hyeon JeongRaphas Co., Ltd., 62, Magokjungang 8-ro 1-gil, Gangseo-gu, Seoul, 07793, Republic of Korea.
Gihyun LeeCollege of Korean Medicine, Dongshin University, 120-9, Dongsindae-gil, Naju-si, Jeollanam-do, 58245, Republic of Korea.
Soo-Yeon ParkDepartment of Ophthalmology, Otolaryngology and Dermatology, College of Korean Medicine, Dongshin University, 120-9, Dongsindae-gil, Naju-si, Jeollanam-do, 58245, Republic of Korea. swallow92@dsu.ac.kr.
Dongshin University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To overcome interruption of skin barrier in transdermal drug delivery, the microneedle (MN) patch penetrates the barrier by punching with its MNs. Setting a needleless patch (NL patch) as the control intervention, this study assessed the efficacy of a biodegradable hyaluronic acid MN patch (BHMN patch) for atopic dermatitis (AD) patients with dry skin. Similar two AD lesions were selected from the extremities of a participant. For one lesion, a BHMN patch was attached for 6-8 h on where an aroma cream was applied (BHMN patch group). Simultaneously, an NL patch was attached on the other lesion as in the BHMN patch group (NL patch group). For 2 weeks, the interventions were conducted 3 times a week. The local scoring AD (L-SCORAD) index, the visual analog scale for pruritus and skin dryness, skin hydration, the transepidermal water loss (TEWL), and safety were assessed. Fifteen participants finished this trial with no dropouts. Both groups improved the L-SCORAD index after 2 weeks (p < 0.05), but the score of the BHMN patch group decreased more than that of the NL patch group (p < 0.05). The other outcomes, except for the TEWL, also showed statistical significance in intragroup comparisons. Nevertheless, none of the other outcomes showed statistical significance in intergroup comparisons. The TEWL showed no statistical significance even in intragroup comparison. Recoverable minor adverse events were reported in three cases. Considering the result of L-SCORAD index, the BHMN patch may be effective for ameliorating AD. However, a large-scale confirmatory trial is necessary to reassess other outcomes.Trial Registration: This study was registered with the Clinical Research Information Service, Republic of Korea (Submitted date: 04/01/2022, Registered date: 23/02/2022, The first participant enrollment: 01/12/2021, Registration No. KCT0007037).

Indexed as

Dermatitis, AtopicHumansHyaluronic AcidPruritusSkinTerpenesTreatment Outcomebis(helenalinyl)malonateHyaluronic AcidTerpenesAtopic dermatitisBiodegradableDry skinMicroneedle patchRandomized controlled trial

Identifiers

PMID36242622
OpenAlexW4306293875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.